[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

项目	WBC高值		RBC高值		WBC低值		RBC低值
项目	分装	未分装	分装	未分装	分装	未分装	分装	未分装
靶值范围	10~50	10~50	30~100	30~100	0~10	0~10	0~15	0~15
MIN	17.16	10.12	44.00	39.16	0.00	0.00	0.00	0.00
MAX	47.96	30.36	99.00	80.52	8.36	7.04	10.56	11.44
极差	30.80	20.24	55.00	41.36	8.36	7.04	10.56	11.44
x	27.86	22.96	65.40	56.07	3.59	3.12	5.00	5.84
s	6.88	4.40	12.85	12.36	2.34	1.58	3.00	2.83
CV	0.25	0.19	0.20	0.22	0.65	0.51	0.60	0.48

项目	WBC高值		RBC高值		WBC低值		RBC低值
项目	分装	未分装	分装	未分装	分装	未分装	分装	未分装
靶值范围	10~50	10~50	30~100	30~100	0~10	0~10	0~15	0~15
MIN	17.16	10.12	44.00	39.16	0.00	0.00	0.00	0.00
MAX	47.96	30.36	99.00	80.52	8.36	7.04	10.56	11.44
极差	30.80	20.24	55.00	41.36	8.36	7.04	10.56	11.44
x	27.86	22.96	65.40	56.07	3.59	3.12	5.00	5.84
s	6.88	4.40	12.85	12.36	2.34	1.58	3.00	2.83
CV	0.25	0.19	0.20	0.22	0.65	0.51	0.60	0.48

1	黄平,周云丽. 尿有形成分检验的现状及发展趋势[J]. 国际检验医学杂志, 2009,30(11):1095-1096.
2	沈薇,顾怡,张乐乐,等.科宝XS型全自动尿有形成分分析仪相关参数的研究[J].诊断学理论与实践,2010,9(6):592-593.
3	张时民. 尿有形成分检查自动化进展和质量保证[J].中国医疗器械信息,2012,18(4):13-22.
4	丛玉隆. 自动化仪器检查尿有形成分的问题与思考[J]. 实用医院临床杂,2012,9(3):1-3.

RichHTML

PDF (PC)